Published on | 7 months ago
Programmes Digital, Industry & Space EITThe European Institute for innovation and technology tries to bridge the gap between innovation and commercialisation. The nine different EIT's each form a large community of companies, universities and organisations and they regularly launch calls for proposals to look for the companies with the highest potential.
The EIT Raw Materials will therefore reopen the KAVA 13 upscaling call on the 21st of March. It aims to accelerate the launch of promising new technologies, products, and services in the raw materials industry (mining, recycling and materials). It targets projects with validated technologies that require additional steps (e.g. testing, demonstration, proof of concept, and scaling) before being market-ready.
Who can apply ?
Key funding details:
They work with regular cut-off dates similar to other Horizon Europe accelerators. The next deadlines are:
More information can be found on this website
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.